#35
Clinical Context
Background information relevant to the evolving cannabis medicine landscape.
This finding is critical because clinicians need to assess cannabis use history when evaluating patients presenting with acute coronary syndrome, particularly younger patients where cannabis use may not be routinely explored. Patients currently using cannabis or considering use should receive counseling about cardiovascular risk, especially those with existing cardiac risk factors or family history of early MI. This evidence supports the need for cannabis use screening in standard cardiovascular risk assessment protocols and documentation in patient health records.
# Clinical Summary
A 2025 study demonstrates that cannabis users face substantially elevated risk for myocardial infarction, a finding with significant implications for cardiovascular risk stratification in clinical practice. The research highlights an important gap in our understanding of cannabis’s cardiovascular effects, particularly regarding THC’s mechanisms of action on cardiac hemodynamics and coronary vasculature. This association is clinically relevant given the expanding legalization and use of cannabis products across North America, which may lead to increased patient exposure without adequate awareness of cardiac risks. Clinicians should incorporate cannabis use into their cardiovascular risk assessment and counseling, particularly for patients with existing coronary artery disease, hypertension, or other cardiac risk factors. The findings suggest a need for further research into dose-dependent effects and whether certain cannabis products or consumption methods carry higher risk than others. Practitioners should routinely screen patients about cannabis use during cardiovascular evaluations and educate patients about potential acute cardiac events associated with use.
💚 Recent observational data linking cannabis use to increased myocardial infarction risk raises important screening and counseling questions for primary care providers, though the magnitude of causality remains uncertain given confounding by smoking status, concurrent substance use, and underlying cardiovascular disease prevalence in cannabis-using populations. The mechanisms proposed—including sympathomimetic effects, coronary vasospasm, and prothrombotic changes—are biologically plausible but incompletely characterized, particularly regarding dose-response relationships and whether risk varies by route of administration or cannabinoid composition. Healthcare providers should view this evidence as a signal to obtain more detailed substance use histories, assess traditional cardiovascular risk factors more thoroughly in patients who use cannabis, and counsel about potential cardiac effects, especially in older adults or those with existing cardiac risk. Until prospective, controlled data emerge, clinicians cannot definitively establish causation or quantify attributable risk, but the current evidence supports incorporating cannabis
💬 Join the Conversation
Have a question about how this applies to your situation?
Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers?
Join the forum discussion →
Have thoughts on this? Share it:
- In the Mix: 30 More Articles — June 26, 2026
- Schedules of Controlled Substances: Placement of 4F-MDMB-BUTICA, ADB-4en-PINACA, 5F-EDMB-PICA, and MMB-FUBICA in Schedule I
- Study links commercial cannabis markets to increased addiction – News-Medical.Net
Get the next evidence review in your inbox
Plain-language summaries of the newest cannabis research, written by a physician. Free to read, and you can unsubscribe at any time.
Join the growing cannabis community. Free. One-click subscribe. Delivered by Substack.
